190 related articles for article (PubMed ID: 35055192)
1. Transcriptome-Guided Drug Repurposing for Aggressive SCCs.
Zauner R; Wimmer M; Dorfer S; Ablinger M; Koller U; Piñón Hofbauer J; Guttmann-Gruber C; Bauer JW; Wally V
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055192
[TBL] [Abstract][Full Text] [Related]
2. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
[TBL] [Abstract][Full Text] [Related]
3. Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis.
Rodeck U; Uitto J
J Invest Dermatol; 2007 Oct; 127(10):2295-6. PubMed ID: 17853916
[TBL] [Abstract][Full Text] [Related]
4. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients.
Hameetman L; Commandeur S; Bavinck JN; Wisgerhof HC; de Gruijl FR; Willemze R; Mullenders L; Tensen CP; Vrieling H
BMC Cancer; 2013 Feb; 13():58. PubMed ID: 23379751
[TBL] [Abstract][Full Text] [Related]
6. Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression.
Pourreyron C; Cox G; Mao X; Volz A; Baksh N; Wong T; Fassihi H; Arita K; O'Toole EA; Ocampo-Candiani J; Chen M; Hart IR; Bruckner-Tuderman L; Salas-Alanis JC; McGrath JA; Leigh IM; South AP
J Invest Dermatol; 2007 Oct; 127(10):2438-44. PubMed ID: 17495952
[TBL] [Abstract][Full Text] [Related]
7. TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa.
Knaup J; Gruber C; Krammer B; Ziegler V; Bauer J; Verwanger T
Anal Cell Pathol (Amst); 2011; 34(6):339-53. PubMed ID: 22002724
[TBL] [Abstract][Full Text] [Related]
8. Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa. A report of 4 patients with 17 primary cutaneous malignancies.
Newman C; Wagner RF; Tyring SK; Spigel GT
J Dermatol Surg Oncol; 1992 Apr; 18(4):301-5. PubMed ID: 1560154
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
Rami A; Łaczmański Ł; Jacków-Nowicka J; Jacków J
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383666
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas.
Illmer J; Zauner R; Piñón Hofbauer J; Wimmer M; Gruner S; Ablinger M; Bischof J; Dorfer S; Hainzl S; Tober V; Bergson S; Sarig O; Samuelov L; Guttmann-Gruber C; Shalom-Feuerstein R; Sprecher E; Koller U; Laimer M; Bauer JW; Wally V
Br J Dermatol; 2023 Dec; 190(1):80-93. PubMed ID: 37681509
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
Arnold AW; Bruckner-Tuderman L; Zuger C; Itin PH
Dermatology; 2009; 219(1):80-3. PubMed ID: 19439919
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and Outcome of Squamous Cell Carcinoma in Epidermolysis Bullosa in Australia and New Zealand.
Kim M; Li M; Intong-Wheeler LRA; Tran K; Marucci D; Murrell DF
Acta Derm Venereol; 2018 Jan; 98(1):70-76. PubMed ID: 28853495
[TBL] [Abstract][Full Text] [Related]
13. Understanding the pathogenesis of recessive dystrophic epidermolysis bullosa squamous cell carcinoma.
South AP; O'Toole EA
Dermatol Clin; 2010 Jan; 28(1):171-8. PubMed ID: 19945632
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa.
Mallipeddi R; Wessagowit V; South AP; Robson AM; Orchard GE; Eady RA; McGrath JA
J Invest Dermatol; 2004 May; 122(5):1302-9. PubMed ID: 15140235
[TBL] [Abstract][Full Text] [Related]
15. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.
Welponer T; Weber DD; Trattner L; Tockner B; Aminzadeh-Gohari S; Leb-Reichl V; Kaufmann A; Zauner R; Wimmer M; Wally V; Felder TK; Strunk D; Koller U; Bauer JW; Kofler B; Guttmann-Gruber C; Piñon Hofbauer J
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):112-123. PubMed ID: 37669776
[TBL] [Abstract][Full Text] [Related]
16. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
Kim M; Murrell DF
Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
[TBL] [Abstract][Full Text] [Related]
17. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.
Arbiser JL; Fan CY; Su X; Van Emburgh BO; Cerimele F; Miller MS; Harvell J; Marinkovich MP
J Invest Dermatol; 2004 Oct; 123(4):788-90. PubMed ID: 15373786
[TBL] [Abstract][Full Text] [Related]
18. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa.
Rokunohe A; Nakano H; Aizu T; Kaneko T; Nakajima K; Ikenaga S; Matsuzaki Y; Murai T; Tamai K; Sawamura D
J Dermatol; 2008 Jun; 35(6):336-40. PubMed ID: 18578710
[TBL] [Abstract][Full Text] [Related]
19. MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa.
Hata H; Abe R; Suto A; Homma E; Fujita Y; Aoyagi S; Shimizu H
Br J Dermatol; 2015 Mar; 172(3):769-73. PubMed ID: 25066310
[TBL] [Abstract][Full Text] [Related]
20. Management of squamous cell carcinoma in a patient with recessive-type epidermolysis bullosa dystrophica.
Yamada M; Hatta N; Sogo K; Komura K; Hamaguchi Y; Takehara K
Dermatol Surg; 2004 Nov; 30(11):1424-9. PubMed ID: 15522026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
